臨床外科65巻11号

2010年10月発行

特集 外科医のための大腸癌の診断と治療 5．大腸癌の外科治療 ■外科治療総論

大腸癌外科治療への分子生物学の臨床応用

著者： 竹政伊知朗¹ 三森功士² 水島恒和¹ 池田正孝¹ 山本浩文¹ 関本貢嗣¹ 土岐祐一郎¹ 森正樹¹

所属機関： ¹大阪大学大学院医学系研究科消化器外科 ²九州大学生体防御医学研究所

ページ範囲：P.219 - P.227

■大腸癌に対する治療法は多様化しており，今後は分子生物学を臨床応用した個別化医療が求められる．

■個別化医療とは，患者の特性に応じて最大の治療効果と最小の副作用が得られる治療を実践することである．

■特性診断には臨床病理診断，OMICS，遺伝子多型解析に環境要因を加えた相互的解析が必要である．

参考文献

1）竹政伊知朗，池田正孝，山本浩文，他：大腸癌の個別化医療に向けて．Fronti Gastroenterol 13：224-231，2008

2）Paik S, Shak S, Tang G, et al：A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351：2817-2826, 2004

3）Harris L, Fritsche H, Mennel R, et al：American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25：5287-5312, 2007

4）van't Veer LJ, Dai H, van de Vijver MJ, et al：Gene expression profiling predicts clinical outcome of breast cancer. Nature 415：530-536, 2002

5）Watanabe T, Kobunai T, Tanaka T, et al：Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum 52：1941-1948, 2009

6）Barrier A, Boelle PY, Roser F, et al：Stage Ⅱ colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24：4685-4691, 2006

7）Jorissen RN, Gibbs P, Christie M, et al：Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 15：7642-7651, 2009

8）竹政伊知朗，池田正孝，山本浩文，他：遺伝子発現プロファイルによる消化器癌転移推測の可能性を探る．分子消化器病 4：35-40，2007

9）Takemasa, I. Higuchi H, Yamamoto H, et al：Construction of preferential cDNA microarray specialized for human colorectal carcinoma：molecular sketch of colorectal cancer. Biochem Biophys Res Commun 285：1244-1249, 2001

10）Yamasaki M, Takemasa I, Komori T, et al：The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol 30：129-138, 2007

11）Chen YD, Zheng S, Yu JK, et al：Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10：8380-8385, 2004

12）Roessler M, Rollinger W, Palme S, et al：Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 11：6550-6557, 2005

13）Watanabe M, Takemsa I, Kawaguchi M, et al：An application of 2-Nitrobenzenesulfenyl（NBS）method to proteomic profiling of human colorectal carcinoma：a novel approach for biomarker discovery. Proteomics Clin Appl 2：925-935, 2008

14）Ritchie SA, Ahiahonu PW, Jayasinghe D, et al：Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients：implications for early screening and detection. BMC Med 8：13, 2010

15）Tomlinson I, Webb E, Carvajal-Carmona L, et al：A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39：984-988, 2007

16）Zanke BW, Greenwood CM, Rangrej J, et al：Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39：989-994, 2007

17）Broderick P, Carvajal-Carmona L, Pittman AM, et al：A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39：1315-1317, 2007

18）Tomlinson IP, Webb E, Carvajal-Carmona L, et al：A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 40：623-630, 2008

19）Tenesa A, Farrington SM, Prendergast JG, et al：Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40：631-637, 2008

20）Tuupanen S, Niittymaki I, Nousiainen K, et al：Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Res 68：14-17, 2008

21）Tuupanen S, Turunen M, Lehtonen R, et al：The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41：885-890, 2009

22）Wong HL, Koh WP, Probst-Hensch NM, et al：Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer：a functional genomics approach. Gut 57：1090-1096, 2008

23）Khambata-Ford S, Garrett CR, Meropol NJ, et al：Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25：3230-3237, 2007

24）Loupakis F, Pollina L, Stasi I, et al：PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27：2622-2629, 2009

25）Cui YH, Liu TS, Zhuang RY, et al：Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J Dig Dis 10：118-123, 2009

26）Simon R：Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 97：866-867, 2005

27）竹政伊知朗，池田正孝，山本浩文，他：網羅的遺伝子・タンパク解析，DNAマイクロアレイ．門田守人，松浦成昭（編）；癌転移のメカニズムがよくわかる　肝転移のすべて．永井書店，2006，pp139-146